Omeros (NASDAQ:OMER) Upgraded to “Hold” by StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

Separately, Needham & Company LLC restated a hold rating on shares of Omeros in a research note on Tuesday, June 4th.

Omeros Stock Down 3.0 %

Shares of NASDAQ:OMER opened at $4.87 on Tuesday. Omeros has a twelve month low of $0.92 and a twelve month high of $5.68. The stock’s 50 day moving average is $4.25 and its 200-day moving average is $3.88. The firm has a market capitalization of $282.17 million, a price-to-earnings ratio of -2.47 and a beta of 1.45.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Equities research analysts anticipate that Omeros will post -1.81 earnings per share for the current fiscal year.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares in the last quarter. Cypress Capital Group raised its holdings in shares of Omeros by 40.0% in the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 10,000 shares in the last quarter. Comerica Bank raised its holdings in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after buying an additional 81,348 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.